30
Participants
Start Date
March 31, 2011
Primary Completion Date
October 31, 2015
Panobinostat
Dose will be assigned at study entry. Patients will take panobinostat orally 3 times a week given on a Monday, Wednesday, Friday schedule, every week. One course is 28 days (4 weeks). Patients will get 2 courses and may receive up to 8 courses total.
Cytarabine
"All patients will receive 70 mg of intrathecal cytarabine on day 0 of course 1. The day 0 dose must be given at least 24 hours prior to initiation of panobinostat. Omit the day 0 dose of intrathecal cytarabine if the patient received intrathecal therapy within 72 hours of treatment.~All patients will receive 70 mg of intrathecal cytarabine on day 29 of course 1-8 in conjunction with their disease evaluation."
Panobinostat
Dose will be assigned at study entry. Patients will take panobinostat orally 3 times a week on a Monday, Wednesday, Friday schedule, every other week. Once course is 28 days (4 weeks). Patients will get 2 course and may receive up to 8 courses of therapy.
New York University Medical Center, New York
Children's Hospital New York-Presbyterian, New York
Levine Children's Hospital at Carolinas Medical Center, Charlotte
University of Miami Cancer Center, Miami
Childrens Hospital Los Angeles, Los Angeles
Seattle Children's Hospital, Seattle
UCSF School of Medicine, San Francisco
Children's National Medical Center, Washington D.C.
Children's Healthcare of Atlanta, Emory University, Atlanta
Lurie Children's Hospital, Chicago
Dana Farber, Boston
Rainbow Babies, Cleveland
Nationwide Childrens Hospital, Columbus
Oregon Health and Science University, Portland
Vanderbilt Children's Hospital, Nashville
Primary Children's, Salt Lake City
Medical College of Wisconsin, Milwaukee
C.S. Mott Children's Hospital, Ann Arbor
Childrens Hospital & Clinics of Minnesota, Minneapolis
St. Jude, Memphis
Collaborators (1)
Novartis
INDUSTRY
Therapeutic Advances in Childhood Leukemia Consortium
OTHER